All stock lists
Mentari Therapeutics, Inc. (NASDAQ:MTRI)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$19.10+$0.75 (+4.09%)
Market cap
$10.5M
Insider Score
Health Score
Analyst consensus
Listed since
May 5, 2014
Website
Insider Score
49/ 100
MTRI Insider Score
Neutral16 qualifying trades · 1 insider · $238.37K bought in the last 90 days
Financial Health Score
Fair
From MTRI’s reported statements · Q3 2026 (trailing 12 months)
Profitability10 / 20
Loses money on what it sells.
- Revenue
- $2.06B
- Net income
- -$12.4M
- Net margin
- -0.6%
Leverage20 / 20
Little or no net debt.
- Total debt
- $0
- Cash
- $1.09B
- Total debt
- $0
Liquidity0 / 20
Owes more within a year than it holds to pay it.
- Current assets
- $1.3M
- Current liabilities
- $2.5M
- Current ratio
- 0.50
Cash generation11 / 20
Roughly cash-neutral.
- Operating cash flow
- -$9.0M
- Free cash flow
- -$9.0M
- FCF margin
- -0.4%
Dilution & runway0 / 20
Heavy dilution — shareholders are paying for the business.
- Shares outstanding
- 0.5M
- Share growth (1y)
- 38.3%
- Cash runway
- 1453 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
MTRI Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | $0.00 | $2.06 B | $0.00 | $820.00 K | $1.12 M | $1.78 M |
| Revenue Growth (YoY) | -100.00 % | 115691.64 % | -100.00 % | -26.24 % | -11.43 % | 38.51 % |
| Cost of Revenue | $221.04 K | $1.75 B | $0.00 | $794.00 K | $716.96 K | $991.69 K |
| Gross Profit | -$221.04 K | $306.94 M | $0.00 | $26.00 K | $403.16 K | $785.47 K |
| SG&A Expense | $1.80 B | $1.87 B | $1.74 M | $1.52 M | $1.53 M | $3.07 M |
| R&D Expense | $206.01 M | $567.89 M | $1.02 M | $631.00 K | $581.61 K | $153.54 K |
| Operating Expenses | $1.79 M | $2.95 M | $2.82 M | $2.15 M | $2.17 M | $3.22 M |
| Operating Income | -$2.01 M | -$3.21 M | -$2.82 M | -$2.12 M | -$1.76 M | -$2.44 M |
| Pretax Income | -$2.00 M | -$4.84 M | -$2.79 M | -$2.03 M | -$1.73 M | -$2.44 M |
| Tax Provision | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$2.33 M | -$5.08 M | -$2.97 M | -$2.03 M | -$1.73 M | -$2.44 M |
| EPS (Basic) | -$4.30 | -$14.30 | -$7.30 | -$5.21 | -$6.08 | -$12.20 |
| EPS (Diluted) | -$4.30 | -$14.30 | -$7.30 | -$5.21 | -$6.08 | -$12.20 |
| Shares Outstanding | 546.95 K | 437.33 K | 404.82 K | 395.45 K | 395.45 K | 200.22 K |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.